Functional tissue-engineered bone-like graft made of a fibrin scaffold and TG2 gene-modified EMSCs for bone defect repair
Source abstract
Abstract
Abstract The transplantation of tissue-engineered scaffolds with stem cells is a promising therapeutic approach for bone defect repair. To improve the therapeutic efficacy of this approach, in this study, a novel biofunctional live tissue-engineered bone-like graft was designed and constructed using a fibrin scaffold loaded with TG2 gene-modified ectomesenchymal stem cells (TG2-EMSCs) derived from nasal respiratory mucosa for bone defect repair. Autocalcification of the cell-free fibrin gel in osteogenic medium with additional alkaline phosphatase (ALP) and the osteogenic differentiation of TG2-EMSCs on the fibrin scaffold were assessed in vitro. The results indicated that the cell-free fibrin gel could autocalcify in the osteogenic medium with ALP and that the overexpression of TG2 by TG2-EMSCs could promote the osteogenic differentiation of these stem cells in the fibrin scaffold. Moreover, TG2 could enhance the deposition of extracellular matrix proteins in the fibrin scaffold, followed by calcification of the bone matrix in vitro. After transplantation into critical-sized cranial defects in rats, the functional tissue-engineered bone-like grafts improved bone regeneration. These results indicate that this tissue-engineered bone-like graft could improve the process of bone defect repair.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · Periodontal Regeneration and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Fearon, J. A., Griner, D., Ditthakasem, K. & Herbert, M. Autogenous bone reconstruction of large secondary skull defects. Plast. Reconstruct. Surg. 139, 427 (2017).10.1097/PRS.0000000000002941 ↗
2. Sagi, H. C., Young, M. L., Gerstenfeld, L., Einhorn, T. A. & Tornetta, P. Qualitative and quantitative differences between bone graft obtained from the medullary canal (with a reamer/irrigator/aspirator) and the iliac crest of the same patient. J. Bone Jt. Surg. Am. ume 94, 2128–2135 (2012).10.2106/JBJS.L.00159 ↗
3. Saeed, H. et al. Mesenchymal stem cells (MSCs) as skeletal therapeutics—an update. J. Biomed. Sci. 23, 1–15 (2016).10.1186/s12929-016-0254-3 ↗
4. Sándor, G. K. et al. Adipose stem cells used to reconstruct 13 cases with cranio‐maxillofacial hard‐tissue defects. Stem Cells Transl. Med. 3, 530–540 (2014).10.5966/sctm.2013-0173 ↗
5. Rinaldo, F. S., Silva, S. G. R. D., Estela, S. C., Jesus, S. E. M. & Sérgio, C. P. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed. Res. Int. 2015, 421746 (2015).
6. Schmidt, J. R. et al. Sulfated hyaluronic acid and dexamethasone possess a synergistic potential in the differentiation of osteoblasts from human bone marrow stromal cells. J. Cell. Biochem. 120, 8706–8722 (2019).10.1002/jcb.28158 ↗
7. Deng, W. et al. EMSCs build an all‐in‐one niche via cell–cell lipid raft assembly for promoted neuronal but suppressed astroglial differentiation of neural stem cells. Adv. Mater. 31, 1806861 (2019).10.1002/adma.201806861 ↗
8. Zhijian et al. Nasal ectomesenchymal stem cells: Multi-lineage differentiation and transformation effects on fibrin gels—ScienceDirect. Biomaterials 49, 57–67 (2015).10.1016/j.biomaterials.2015.01.057 ↗
9. Gao, G. & Cui, X. Three-dimensional bioprinting in tissue engineering and regenerative medicine. Biotechnol. Lett. 38, 203–211 (2016).10.1007/s10529-015-1975-1 ↗
10. Melke, J., Midha, S., Ghosh, S., Ito, K. & Hofmann, S. Silk fibroin as biomaterial for bone tissue engineering. Acta Biomater. 31, 1–16 (2016).10.1016/j.actbio.2015.09.005 ↗
11. Alireza, N., Jamal, A. S., Roza, V. G., Ashraf, H. Z. & Webster, T. J. A review of fibrin and fibrin composites for bone tissue engineering. Int. J. Nanomed. 12, 4937–4961 (2017).10.2147/IJN.S124671 ↗
12. Wu, X., Ren, J. & Li, J. Fibrin glue as the cell-delivery vehicle for mesenchymal stromal cells in regenerative medicine. Cytotherapy 14, 555–562 (2012).10.3109/14653249.2011.638914 ↗
13. Lv, J. et al. Enhanced angiogenesis and osteogenesis in critical bone defects by the controlled release of BMP-2 and VEGF: implantation of electron beam melting-fabricated porous Ti6Al4V scaffolds incorporating growth factor-doped fibrin glue. Biomed. Mater. 10, 035013 (2015).10.1088/1748-6041/10/3/035013 ↗
14. Anitua, E., Zalduendo, M. M., Prado, R., Alkhraisat, M. H. & Orive, G. Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion. J. Biomed. Mater. Res. Part A 103, 1011–1020 (2015).10.1002/jbm.a.35244 ↗
15. Liu, M. et al. Injectable hydrogels for cartilage and bone tissue engineering. Bone Res. 5, 75–94 (2017).
16. Lichte, P., Pape, H. C., Pufe, T., Kobbe, P. & Fischer, H. Scaffolds for bone healing: concepts, materials and evidence. Injury 42, 569–573 (2011).10.1016/j.injury.2011.03.033 ↗
17. Belkin, A. M. Extracellular TG2: emerging functions and regulation. FEBS J. 278, 4704–4716 (2011).10.1111/j.1742-4658.2011.08346.x ↗
18. Wang, Z. & Griffin, M. TG2, a novel extracellular protein with multiple functions. Amino Acids 42, 939–949 (2012).10.1007/s00726-011-1008-x ↗
19. Cavelier, S., Dastjerdi, A. K., McKee, M. D. & Barthelat, F. Bone toughness at the molecular scale: a model for fracture toughness using crosslinked osteopontin on synthetic and biogenic mineral substrates. Bone 9, 19706 (2018).
20. Maria, N. Transglutaminases in mineralized tissues. Front. Biosci. A 11, 1591 (2006).10.2741/1907 ↗
21. Weisel, J. W. & Litvinov, R. I. In Fibrous Proteins: Structures and Mechanisms (eds Squire, J. M. & Parry, D. A. D.) 405–456 (Cham, 2017).10.1007/978-3-319-49674-0_13 ↗
22. Komáromi, I., Bagoly, Z. & Muszbek, L. Factor XIII: novel structural and functional aspects. J. Thrombosis Haemostasis 9, 9–20 (2011).10.1111/j.1538-7836.2010.04070.x ↗
23. Barsigian, C., Stern, A. M. & Martinez, J. Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators. J. Biol. Chem. 266, 22501 (1991).10.1016/S0021-9258(18)54600-7 ↗
24. Al-Jallad, H. F. et al. Transglutaminase activity regulates osteoblast differentiation and matrix mineralization in MC3T3-E1 osteoblast cultures. Matrix Biol. 25, 135–148 (2006).10.1016/j.matbio.2005.11.001 ↗
25. Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical trials worldwide to 2017: An update. J. Gene Med. 20, e3015 (2018).10.1002/jgm.3015 ↗
26. Crystal, R. G. Adenovirus: the first effective in vivo gene delivery vector. Hum. Gene Ther. 25, 3–11 (2014).10.1089/hum.2013.2527 ↗
27. Jeitner, T. M., Delikatny, E. J., Ahlqvist, J., Capper, H. & Cooper, A. J. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 69, 961–970 (2005).10.1016/j.bcp.2004.12.011 ↗
28. Carrion, B., Janson, I. A., Kong, Y. P. & Putnam, A. J. A safe and efficient method to retrieve mesenchymal stem cells from three-dimensional fibrin gels. Tissue Eng. Part C 20, 252–263 (2014).10.1089/ten.tec.2013.0051 ↗
29. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).10.1038/nm.3793 ↗
30. Nurminsky, D. et al. Transglutaminase 2 regulates early chondrogenesis and glycosaminoglycan synthesis. Mech. Dev. 128, 234–245 (2011).10.1016/j.mod.2010.11.007 ↗
31. Li, B., Tian, X., Hu, R., Xu, F. & Zhao, J. Mechanism of BMP and TG2 in mesenchymal stem cell osteogenesis. Eur. Rev. Med. Pharm. Sci. 19, 4214–4219 (2015).
32. Yin, X., Chen, Z., Liu, Z. & Song, C. Tissue transglutaminase (TG2) activity regulates osteoblast differentiation and mineralization in the SAOS-2 cell line. Braz. J. Med. Biol. Res. 45, 693–700 (2012).10.1590/S0100-879X2012007500060 ↗
33. Wu, M., Chen, G. & Li, Y.-P. TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 4, 1–21 (2016).10.1038/boneres.2016.9 ↗
34. Beazley, K. E. & Nurminskaya, M. BMP2 cross-linked by transglutaminase 2 to collagen-plla scaffold promotes osteogenic differentiation in mesenchymal stem cells. Biotechnol. Lett. 36, 1901–1907 (2014).10.1007/s10529-014-1551-0 ↗
35. Filipowska, J., Tomaszewski, K. A., Niedźwiedzki, Ł., Walocha, J. A. & Niedźwiedzki, T. The role of vasculature in bone development, regeneration and proper systemic functioning. Angiogenesis 20, 291–302 (2017).10.1007/s10456-017-9541-1 ↗
36. Abdeen, A. A. & Saha, K. Manufacturing cell therapies using engineered biomaterials. Trends Biotechnol. 35, 971–982 (2017).10.1016/j.tibtech.2017.06.008 ↗
37. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).10.1016/j.cell.2006.06.044 ↗
38. Guilak, F. et al. Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell 5, 17–26 (2009).10.1016/j.stem.2009.06.016 ↗
39. Soluri, M. F. et al. Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2‐expressing cells. FASEB J. 33, 2327–2342 (2019).10.1096/fj.201800054RRR ↗
40. Fortunati, D. et al. of collagen I by tissue transglutaminase provides a promising biomaterial for promoting bone healing. Amino Acids 46, 1751–1761 (2014).10.1007/s00726-014-1732-0 ↗
41. Kaartinen, M. T., El‐Maadawy, S., Räsänen, N. H. & McKee, M. D. Tissue transglutaminase and its substrates in bone. J. Bone Miner. Res. 17, 2161–2173 (2002).10.1359/jbmr.2002.17.12.2161 ↗